Background/aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking.
Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the Asan Medical Center, Seoul, Korea.
Results: Between July 2013 and October 2018, adalimumab therapy was started in a total of 100 patients with UC (65 males [65.0%]; median age, 39.5 years [interquartile range, 23.3 to 49.8 years]; and median disease duration, 3.0 years [interquartile range, 1.0 to 7.0 years]). The median duration of adalimumab therapy was 13.5 months (interquartile range, 4.0 to 32.0 months). Eight of 100 patients (8.0%) received induction therapy only, four (4.0%) of whom ultimately underwent colectomy. Of 92 patients who received adalimumab maintenance therapy, 30 (30.0%) stopped adalimumab therapy due to loss of response, and one patient (1.0%) was lost to follow-up. Among the 92 patients who received adalimumab maintenance therapy, the cumulative proportions of patients remaining on adalimumab maintenance therapy were 70.0% at 1 year and 48.9% at 5 years. High partial Mayo score after 8 weeks of adalimumab therapy (hazard ratio [HR], 1.217; 95% confidence interval [CI], 1.040 to 1.425; p=0.014) and a history of exposure to two biologic agents before adalimumab therapy (HR, 4.722; CI, 1.033 to 21.586; p=0.045) were predictors of adalimumab discontinuation.
Conclusions: Long-term outcomes of adalimumab therapy in Korean UC patients appear to be comparable to those in previously published Western studies. Furthermore, previous exposure to multiple biologic agents before adalimumab therapy and disease activity after 8 weeks of adalimumab therapy were predictors of adalimumab discontinuation.
Keywords: Adalimumab; Colitis; Prognosis; Tumor necrosis factor-alpha; ulcerative.
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose EscalationC Taxonera et al. Dig Dis Sci 62 (2), 481-490. PMID 27995400.In this "real-life" cohort of UC patients on maintenance treatment with adalimumab, anti-TNF-naïve patients had significantly better long-term outcomes. Adalimumab dose e …
Long-term Assessment of Clinical Response to Adalimumab Therapy in Refractory Ulcerative ColitisM Hussey et al. Eur J Gastroenterol Hepatol 28 (2), 217-21. PMID 26587866.Our study shows adalimumab is an effective and safe long-term therapy for moderately active UC refractory to other treatments. While this data is encouraging, further wor …
Long-term Outcomes of Infliximab Treatment and Predictors of Response in 195 Patients With Ulcerative Colitis: A Hospital-Based Cohort Study From KoreaH Seo et al. Scand J Gastroenterol 52 (8), 857-863. PMID 28502189.The long-term efficacy of IFX in a large, real-life cohort of Korean UC patients appears to be comparable to that in previously published Western studies.
The Impact of Biological Interventions for Ulcerative Colitis on Health-Related Quality of LifeK LeBlanc et al. Cochrane Database Syst Rev (9), CD008655. PMID 26393522. - ReviewThese results suggest that biologics have the potential to improve HRQL in UC patients. High quality evidence suggests that infliximab provides a clinically meaningful im …
Down-titration and Discontinuation Strategies of Tumor Necrosis Factor-Blocking Agents for Rheumatoid Arthritis in Patients With Low Disease ActivityN van Herwaarden et al. Cochrane Database Syst Rev (9), CD010455. PMID 25264908. - ReviewWe can conclude, mostly based on moderate quality evidence, that non-disease activity guided dose reduction of etanercept 50 mg weekly to 25 mg weekly, after at least thr …